Research › Fact Sheets › GILD

GILEAD SCIENCES, INC.

LISTEDNASDAQ

SYMBOLGILD

SIC2836

STATE OF INC.DE

FISCAL YEAR ENDSDecember 31

CIK882095

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)	Amount	%
Total debt	24,937	52.3
Stockholders' equity	22,703	47.7
Total capitalization	47,640	100.0

1,239,955,155 shares outstanding at 31 July 2026 (cover page of the 10-Q filed 6 August 2026).

LONG-TERM DEBT 12/31/25

($ millions)	Amount
Long-term debt, incl. current maturities	24,937
Long-term debt, noncurrent	22,129
Current maturities	2,807

CAPITAL STOCK 12/31/25

Common shares authorized	5,600,000,000
Common shares issued	1,241,000,000
Par or stated value per share ($)	0.001
Preferred stock ($ millions)	0
Outstanding at 7/31/26	1,239,955,155

DIVIDENDS DECLARED/PAID

Fiscal year	Per share $	Payout %
2025	3.16	46.6
2024	3.08	810.5
2023	3.00	66.7
2022	2.92	80.2
2021	2.84	57.6

HISTORY AND BUSINESS

HISTORY: Incorporated in Delaware.

BUSINESS: Classified by the SEC under Standard Industrial Classification 2836, Biological Products, (No Diagnostic Substances). Large accelerated filer. Principal executive office: 333 Lakeside Dr, Foster City, CA 94404. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)	12/31/25	12/31/24	12/31/23
Revenues	29,443	28,754	27,116
Cost of revenues	6,234	6,251	6,498
Research and development	5,799	5,907	5,718
Selling, general and administrative	5,774	6,091	6,090
Depreciation and amortization	370	381	354
Operating income	10,022	1,662	7,605
Interest expense	1,024	977	944
Income before income taxes	9,796	690	6,859
Income taxes	1,286	211	1,247
Net income	8,510	480	5,665
Earned per share, diluted ($)	6.78	0.38	4.50
Dividends per share ($)	3.16	3.08	3.00

CONSOLIDATED BALANCE SHEET

($ millions)	12/31/25	12/31/24
Receivables, net	4,913	4,420
Inventories	1,774	1,710
Total current assets	18,342	19,173
Property, plant and equipment, net	5,606	5,414
Goodwill	8,314	8,314
Total assets	59,023	58,995
Total current liabilities	11,813	12,004
Long-term debt	22,129	24,896
Stockholders' equity	22,703	19,330
Total liabilities and equity	59,023	58,995

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year ended	Revenues	Oper. income	Net income	Net margin %	EPS diluted $	Div. per share $	Oper. cash flow	Capital expend.	Free cash flow	Total assets	Total liabilities	Total debt	Stockholders' equity	ROE %	Debt / equity
12/31/25	29,443	10,022	8,510	28.9	6.78	3.16	10,019	563	9,456	59,023	36,405d	24,937	22,703	37.5	1.10
12/31/24	28,754	1,662	480	1.7	0.38	3.08	10,828	523	10,305	58,995	39,749d	26,710	19,330	2.5	1.38
12/31/23	27,116	7,605	5,665	20.9	4.50	3.00	8,006	585	7,421	62,125	39,376d	24,987	22,833	24.8	1.09
12/31/22	27,281	7,330	4,592	16.8	3.64	2.92	9,072	728	8,344	63,171	41,962d	25,229	21,240	21.6	1.19
12/31/21	27,305	9,918	6,225	22.8	4.93	2.84	11,384	579	10,805	67,952	46,888d	26,695	21,069	29.5	1.27
12/31/20	24,689	4,071	123	0.5	0.10	2.72	8,168	650	7,518	68,407	50,186d	31,402	18,202	0.7	1.73
12/31/19	22,449	4,287	5,386	24.0	4.22	2.52	9,144	825	8,319	61,627	38,977d	24,593	22,525	23.9	1.09
12/31/18	22,127	8,200	5,455	24.7	4.17	2.28	8,400	924	7,476	63,675	42,141d	27,322	21,387	25.5	1.28
12/31/17	26,107	14,124	4,628	17.7	3.51	2.08	11,898	590	11,308	70,283	49,782d	33,542	20,442	22.6	1.64
12/31/16	30,390	17,633	13,501	44.4	9.94	1.84	17,047	748	16,299	56,977	37,614d	26,346	18,887	71.5	1.39

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

GILEAD SCIENCES, INC.
CIK 882095 · EIN 94-3047598

PRINCIPAL OFFICE:

333 Lakeside Dr, Foster City, CA 94404
Tel.: 6505743000

INCORPORATED:

Delaware

INDUSTRY (SEC SIC CODE):

2836 · Biological Products, (No Diagnostic Substances)

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 24 February 2026

FORMER NAMES:

GILEAD SCIENCES INC

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

8/6/26	10-Q	period 6/30/26
8/4/26	8-K	period 8/4/26
5/20/26	8-K	period 5/14/26
5/7/26	10-Q	period 3/31/26
5/7/26	8-K	period 5/7/26
5/4/26	8-K	period 4/30/26
4/28/26	8-K	period 4/28/26
3/20/26	DEF 14A	period 4/30/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/24/26) · 10-K FY2024 (filed 2/28/25) · 10-K FY2023 (filed 2/23/24) · 10-K FY2022 (filed 2/22/23) · 10-K FY2021 (filed 2/23/22) · 10-K FY2020 (filed 2/25/21) · 10-K FY2019 (filed 2/25/20) · 10-K FY2018 (filed 2/26/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.